1 / 49

Veterinary Serum and Vaccine Research Institute in Egypt

Veterinary Serum and Vaccine Research Institute in Egypt. ( VSVRI ). Present and Future Prospect. By. Seham A. El-Zeedy Director of VSVRI. Historical. Background.

adonia
Download Presentation

Veterinary Serum and Vaccine Research Institute in Egypt

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Veterinary Serum and Vaccine Research Institute in Egypt ( VSVRI ) Present and Future Prospect By. Seham A. El-Zeedy Director of VSVRI

  2. Historical Background

  3. Since 1903 the VSVRI has been established on an area of about 23 square hectares in the Red Mountain area of the Abbassia district, east Cairo. The VSVRI is one of the oldest and prestigious institutes in the Middle East and Africa. At the beginning, the scope of its responsibility was limited to production of vaccine and antiserum, for protection of cattle against Rinderpest (cattle plague).

  4. The laboratory’s mission has continued to grow. The next period witnessed considerable laboratory expansions and new building constructions in response to the demands.

  5. Mission

  6. Production of highly efficient vaccines, Sera and Diagnostic Reagent utilizing both reference and local isolates based on the international standards to guarantee protection of animals and poultry from different diseases. In addition, • preparation of combined vaccines to save the effort, time, stress and money. • Conducting researches for improvement and innovation of Veterinary Vaccines, Sera and Diagnostic Reagents.

  7. Vision

  8. Completion of high Contemned BSl3 Laboratories for production of FMD & Avian Influenza Vaccines. Certified the current production facilities according to GMP requirements for veterinary vaccine production. Improvement and innovation of Veterinary Vaccines, Sera and Diagnostic Reagent. Using the molecular biology for improvement the vaccine and diagnostic reagents. Expanding training on up to date technologies. Completion of high Containment BSL-3 Laboratories for production of FMD & Avian Influenza Vaccines. Certified the current production facilities according to GMP requirements for veterinary vaccine production. Improvement and innovation of Veterinary Vaccines, Sera and Diagnostic Reagent. Using the molecular biology for improvement the vaccine and diagnostic reagents. Expanding training on up to date technologies.

  9. The VSVRI Consists of 14 Research Departments

  10. 5 Research Department for Production of Bacterial Biologics • Aerobic Bacterial Vaccines • Research Department. • Anaerobic Bacterial Vaccines • Research Department. • Bacterial Sera and Antigens • Research Department. • Bacterial Diagnostic products • Research Department. • Parasitic Vaccines • Research Department.

  11. 8 Research Department for Production of Viral Biologics • FMD Research Department . • Rift Valley Fever Vaccine Department. • Pox Vaccines Research Department. • Rinderpest Vaccine Research Department. • Rinderpest like diseases vaccine • Research Department. • Pet animal Vaccines Research Department. • Equine Vaccines Research Department. • Newcastle and other Viral Poultry • Vaccines Department . Genetic Engineering Department

  12. Research Team

  13. Assistant Researchers Consultants Research Assistants Chief Researchers Researchers Senior Researchers Total Research Team 218

  14. Employees and workers

  15. Contract Employees Administrative Temporary Workers Workers Employees and workers 654

  16. Attenuated Rift Valley Fever Vaccine. Attenuated Bovine Ephemeral Fever Vaccine. P.P.R. Vaccine (Egypt 87). Sheep Pox Vaccine. Camel Pox Vaccine. African Horse Sickness Attenuated Polyvalent Vaccine. Attenuated Canine Parvo Vaccine.

  17. Bivalent Foot and Mouth Disease Vaccine. Bivalent Inactivated Foot and Mouth Disease Oil Vaccine types ( O1 & A ). Inactivated Rift Valley Fever Vaccine. Inactivated Bovine Ephemeral Fever Vaccine. Inactivated Respiratory Virus Diseases Vaccine “Pneumo 3”. Inactivated Respiratory Virus Diseases Vaccine “Pneumo 4”

  18. Inactivated Bovine Rota (BR), Corona (BC) and Toxigenic E. Coli K99 Vaccine (Entero-3). Bivalent Inactivated African Horse Sickness Vaccine. Monovalent Inactivated Freeze Dried Equine Influenza Vaccine. Inactivated Rabies Vaccine. Inactivated Tissue Culture Rabies Vaccine.

  19. Haemorrhagic Septicaemia Oil Adj. Vaccine (For Cattle). Oil Adjuvinated Polyvalent Pneumo bac Pasteurellosis Vaccine. Gel Adjuvinated Polyvalent Pneumo bac Pasteurellosis Vaccine. BCG Vaccine. Brucella Abortus Vaccine (St. 19). Brucella Melitensis Vaccine (Rev.1). Blackleg and Gas Gangrene Vaccine. Polyvalent Clostridial Vaccine.

  20. Tube Agglutination Brucella Antigen. Buffer Acidified Plate Brucella Antigen. Rose Bengal Brucella Antigen. Milk Ring Test Brucella Antigen. Rivanol Brucella Antigen. Rivanol solution. Mammalian P.P.D. Tuberculin. Bovine P.P.D. Tuberculin Rift Valley Fever Antigen.

  21. Antitetanic Serum

  22. Newcastle Vaccine (Hitchner B1). Newcastle Vaccine (LaSota). Newcastle Vaccine (Komarov). Lasota & IB. Hitchner B1 and Infectious Bronchitis Vaccine. Infectious Bursal Disease Vaccine (D78 Strain).

  23. Infectious Bursal Disease Vaccine (Bursa Vac. strain). Fowl Pox Vaccine. Pigeon Pox Vaccine. Duck Virus Hepatitis Vaccine. Duck Plague Vaccine.

  24. Inactivated Newcastle And Gumboro Vaccine. Inactivated Newcastle , IB and EDS. Inactivated Newcastle Vaccine (Oil adj.). Inactivated Oil Emulsion Avian Influenza Vaccine. Inactivated Pigeon Paramyxo Vaccine. Inactivated Rabbit Haemorrhagic Virus Vaccine.

  25. Polyvalent Fowl Cholera Vaccine (Oil Adj.) Polyvalent Rabbit Pasteurellosis Vaccine (Formalized). Polyvalent Rabbit Pasteurellosis Vaccine (Oil Adj.). Rabbit Clostridial Entertoxaemia Bloat Vaccine Infectious Coryza (Oil Adj.) Vaccine. Inactivated Spirochetosis Vaccine. Chicken Necrotic Oil Vaccine. Chicken Necrotic Gel Vaccine.

  26. Salmonella Pullorum Antigen(Tube Agglutination). Salmonella Pullorum Stained Antigen(polyvalent) . Paratyphoid Antigen. AvianP.P.D.Tuberculin.

  27. US Naval American Medical Research Unit (NAMRU 3). Us Department of State Biosecurity Engagement Program Food and Ogriculture Organization (FAO). Offices of International Epizootic (OIE). World Health Organization ( WHO )

  28. Avian Flu Cases in Egypt Raise Alarms

  29. The First HPAI outbreak was announced on February 2007. The disease is now endemic. Vaccine started on March 2007 depending on importation of H5N1andH5N2 inactivated Vaccines from different counters. The key to preventing human infections with AI is to control poultry outbreaks of AI . Developing of national laboratory for vaccine production to produce AI vaccine from local isolates is must.

  30. Biosafety and Biosecurity laboratory Design Criteria

  31. Laboratory location. Wipe – clean surface. Heating , ventilation and air – conditioning(HVAC) System. Directional airflow and cascade negative pressure. Laboratory furniture and equipment . Laboratory rooms , size and orientation. Sample reception. Double door autoclave and decontamination Chamber for solid waste materials . Water supply and sewerage system. Electrical system.

  32. Essential Building Princiles

  33. Gloves, gownt, masks Biosafety cabinet, Respiratory protection Vaccines & autoclaves Primary containment barriers is the barriers between agent and man.

  34. Air tight rooms. Air handling. Air locks. Showers, laundry. Sewage treatment. Waste disposal. Sterilization. Equipment. Secondary containment barrier is the barrier between agents and Environment to provide protection for individual outside the lab. Walls Fences, Security Quarantine Tertiary containment barrier

  35. Modifiction of the existance Laboratory to be BSl-3

  36. The potential threat of Avian flu and need for appropriate facilities to work with HPAI raise design issues of protection.

  37. Electric room Exit Electricity room Compact area Washing W.C W.C Steril. Blending & Filling & Capping Kitchen Control Hall Inactivation Lab. Refrigerator Doctors Office Closet Ref. Ref. Freez. Ref. Harvestation Inoculation Lab. After Inoculation Incubator Pre Inoculation Incubator Dressing Room Electricity Room Dressing Room Receiving egg Compact area Compact area

  38. Develop a training program All personnel must met the institutional expectation in term of high containment practices

  39. Who should be trained and when ?

  40. Training of all personnel entering a containment facility must be done and documented Training program specific to scientists needs and knowledge Training and evaluation should occur before personnel starts the job

  41. Acknowledgment • U.S National Academy of Sciences. • U.S Department of States Biosecurity • Engagement Program. • -Turkish Academy of Sciences Seham A. El-Zeedy sehamelzeedy@hotmail.com

More Related